Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA

Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance mutations together with efficacy in CNS metastases in patients with non-small-cell lung cancer (NSCLC). Here we descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuboi, Masahiro, Weder, Walter, Escriu, Carles, Blakely, Collin, He, Jianxing, Dacic, Sanja, Yatabe, Yasushi, Zeng, Lingmin, Walding, Andrew, Chaft, Jamie E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530153/
https://www.ncbi.nlm.nih.gov/pubmed/34278827
http://dx.doi.org/10.2217/fon-2021-0549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530153/
https://www.ncbi.nlm.nih.gov/pubmed/34278827
http://dx.doi.org/10.2217/fon-2021-0549

Ejemplares similares